Howard University Telehealth Training Center
HUTTC Home | About | News | Current Projects | Past Projects | On-Demand Videos and Podcasts

5. Culturally Competent Care for Substance Users Diagnosed with HIV Disease

Summary

Although there is limited evidence that some drugs of abuse may directly affect HIV progression and treatment, the primary effects involve factors that may limit patients’ access or adherence to HAART. Studies have demonstrated that substance abusers who adhere to HAART are likely to experience outcomes similar to those of adherent patients who are not substance abusers—underscoring the importance of carefully integrated therapy for both substance abuse and HIV.

Increased access to HIV testing among substance users has been shown to lead to more users’ initiating HAART, although in some areas expanded testing will require different policy strategies, such as those involving:

  • HIV testing and counseling services in substance use treatment facilities
  • Harm-reduction programs like needle and syringe exchange programs
  • Access to medical treatments like methadone and buprenorphine

In addition, < 17% of US substance users who require treatment for substance use in fact access treatment programs.

In the belief that substance users’ multiple social, medical, and economic challenges could mean they are less likely to adhere to antiretroviral treatment, many clinicians have been reluctant to initiate HAART in substance users. However, a number of studies have demonstrated that substance users who are in treatment for their substance use have rates of antiretroviral adherence similar to those of non-substance users, pointing to the importance of providing comprehensive treatment programs that address both substance use and HIV disease at the same time.

A major challenge of providing simultaneous treatment for substance use and HIV disease is the range of interactions that can occur between opioid replacement medications and antiretroviral agents. For example, a number of antiretrovirals can decrease or increase methadone levels, and clinicians should monitor patients for signs and symptoms of methadone withdrawal or toxicity when initiating or discontinuing HAART. However, most antiretrovirals, including those that alter buprenorphine levels, do not cause symptoms of buprenorphine withdrawal or toxicity. Interactions between antiretrovirals and other medications used to treat substance use—naltrexone, acamprosate, and disulfiram—are limited and primarily involve oral formulations of certain protease inhibitors.

Information about interactions between substance abuse treatments and antiretroviral agents—as well as about numerous other drug-drug interactions with antiretrovirals—is available online at sites sponsored by the University of California, San Francisco, and the University of Liverpool.

« BACK

NEXT »